facebook twitter linkedin

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.

Kraków, 13 May 2011  -  On 12 May 2011, during this year’s edition of the “Masters of Innovation” competition, organized along with the Central European Forum of Biotechnology and Innovative BioEconomy – BioForum 2011, Selvita was voted the most innovative biotechnology company in the region. The participants of the competition were  the most innovative enterprises from the biotech sector in the Eastern and Central European region.
The main criterion for the evaluation of participants were the R&D projects run by a company and their innovation. Additionally, the business model, and aspects such as how effectively a company finds opportunities to finance its’ research and development activities and its implementation, were also assessed.
The potential of the R&D projects carried out by the companies, as well as the companies themselves, were assessed and evaluated by an international jury, including experts such as:
  • Oliver Murphy, Deloitte (Poland)
  • Michal Kostka, JIC, South Moravian Innovation Centre (Czech Republic)
  • Heinrich Cuypers, BioCon Valley (Germany)
  • Kate Gunning, BioVisability (USA)
  • Roland Kozlowski – Lectus Therapeutics (UK){mosimage}
Selvita’s CEO Pawel Przewiezlikowski and Dr Milosz Gruca, Selvita’s Head of Biology Department, received the award of “Masters of Innovation” 
from the hands of the Marshal of Łódzkie Vovoidship, naming Selvita the most innovative company in the Eastern and Central European region. 
About the competition:  “Masters of Innovation” is a competition established to highlight Eastern and Central European biotechnology companies, which excel in innovations through actions, including, but not limited to, leading cutting edge R&D projects. Another aspect which plays and important role in the assessment,  is if and how the companies commercialize their projects. The aim of the competition is to emerge the true leader of biotechnology in the ECE region.
About Selvita: Selvita is a Polish, privately-owned, biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders as well as provision of non-clinical research services. It was established and 2007 and currently employs 96 scientists, including 33 PhDs. SELVITA has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2012. The most advanced programs at Selvita are SEL103 for the symptomatic treatment of Alzheimer’s disease and SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in solid and hematopoietic tumors.